Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non‐Hodgkin lymphoma

• Κύριοι συγγραφείς: Masato Fukae (Συγγραφέας), Kyle Baron (Συγγραφέας), Masaya Tachibana (Συγγραφέας), John Mondick (Συγγραφέας), Takako Shimizu (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2024-10-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Valemetostat is an EZH2/1 inhibitor that has been approved in Japan for the treatment of patients with relapsed/refractory adult T‐cell leukemia/lymphoma, based mainly on results from a single‐arm phase II trial. It is currently under investigation worldwide for the treatment of other non‐H...